Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Sanofi, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Sanofi, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Sanofi, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Sanofi, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
Sanofi, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Sanofi, Medical Equipment, Deal Details 14
Asset Purchase 14
Sanofi Plans to Acquire Medical Device Assets 14
Venture Financing 15
Portal Instruments Raises USD25 Million in Series B Financing 15
Portal Instruments Raises USD11 Million in Series A Venture Financing 16
Partnerships 17
Abiogen Pharma Enters Into Licensing Agreement With Genzyme 17
Berg Enters into Research Agreement with Sanofi 18
Sanofi and Voluntis Enter into Agreement 19
Sanofi and Verily Life Sciences Form Joint Venture 20
Global Genomics Enters into Research Agreement with Sanofi 21
Google Life Sciences Enters into Agreement with Sanofi 22
Veracyte Enters into Co-Promotion Agreement with Genzyme 23
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 24
Genzyme Extends Co-Promotion Agreement with Veracyte 25
Sanofi Enters into Co-Development Agreement with Medtronic 26
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 27
HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 28
Genzyme Enters Into Co-Marketing Agreement With Veracyte 29
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30
Curetis Enters Into Agreement With Sanofi Pasteur For Unyvero Platform 31
Institut Pasteur Korea Enters Into Co-Development Agreement With Sanofi-Aventis Korea 32
Voluntis and CERITD Enters Into Co-Development Agreement With Sanofi 33
Merger 34
Sanofi Japan and Genzyme Japan Merge 34
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 35
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 36
Equity Offering 37
JHL Biotech Raises USD80 Million in Private Placement of Shares 37
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 38
Debt Offering 39
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 39
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 40
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 41
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 42
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 43
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 44
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 45
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 47
Sanofi Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 48
Asset Transactions 50
Lupin May Acquire Pulmojet from Zentiva 50
Nichi-iko Pharma To Acquire Business From Sanofi-Aventis 51
Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 52
Acquisition 54
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 54
L’Oreal Plans To Sell Its Stake In Sanofi 55
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 56
Sanofi Completes Acquisition Of Pluromed 58
Sanofi-Aventis Completes Acquisition Of Genzyme 59
Sanofi – Key Competitors 61
Sanofi – Key Employees 62
Sanofi – Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Joint Venture 77
Recent Developments 79
Strategy And Business Planning 79
Jul 05, 2016: Sanofi Enters Into Confidentiality Agreement With Medivation And Will Be Provided Due Diligence Access And Confidential Information 79
Apr 19, 2016: Sanofi Invests €300 Million To Expand Biologics Site in Belgium 80
Financial Announcements 81
Nov 02, 2017: Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed 81
Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 88
Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 94
Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 96
Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 102
Oct 28, 2016: Sanofi Announces Strong Q3 2016 Results 110
Jul 29, 2016: Sanofi Announces Q2 2016 Results 116
Jul 29, 2016: Royalty report for Q2 2016 and update on lixisenatide (Lyxumia/Adlyxin) and iGlarLixi 123
Apr 29, 2016: Solid Performance in the First Quarter of 2016 with Business EPS up 5.3% at Constant Exchange Rates 124
Feb 09, 2016: Sanofi Delivered 2015 Business EPS Up 8.5% On A Reported Basis And Stable At Constant Exchange Rates Consistent With Guidance 130
Corporate Communications 137
Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia 137
Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication 138
Apr 05, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee 140
Mar 02, 2017: Sanofi’s Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charles as New Independent Directors 141
Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 142
Jan 30, 2017: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs 143
Sep 30, 2016: Sanofi Appoints Alan Main to Executive Committee and Executive Vice President, Consumer Healthcare 144
Sep 07, 2016: Sanofi Appoints New Research Head for Immunology and Inflammation 145
Sep 06, 2016: Sanofi Board Of Directors Provides Update 146
Jun 02, 2016: Sanofi India Announces Appointment of Chairman of the Board of Directors 147
May 23, 2016: Sanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap 2020 148
Mar 29, 2016: Sanofi Appoints Dr. Yong-Jun Liu as Head of Research 149
Mar 10, 2016: Sanofi Appoints Dr. Ameet Nathwani to Executive Committee and Executive Vice President, Group Chief Medical Officer 150
Government and Public Interest 151
Jun 13, 2016: Sanofi Files Definitive Consent Solicitation To Remove And Replace Medivation’s Board 151
Jun 01, 2016: Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation’s Board of Directors 152
Other Significant Developments 153
Nov 16, 2017: Blue Cross and Blue Shield Companies Partner with Onduo on Three State Pilot Programs to Address Diabetes 153
Sep 25, 2017: Innovation Health Announces Pilot Program with Sanofi to Improve Care Delivery for People Living with Type 2 Diabetes 154
Oct 10, 2016: BIOASTER, bioMerieux, ESPCI, GSK, Hospices Civils de Lyon and Sanofi join forces against sepsis 155
May 25, 2016: Sanofi Files Consent Solicitation To Remove and Replace Medivation’s Board 157
Apr 19, 2016: Sanofi Invests €300 Million To Expand Biologics Site in Belgium 160
Apr 19, 2016: Sanofi Invests €300 Million in its Biologics Site in Belgium to Develop its Monoclonal Antibodies Portfolio 161
Appendix 162
Methodology 162
About GlobalData 162
Contact Us 162
Disclaimer 162
Sanofi, Medical Equipment, Key Facts, 2016 2
Sanofi, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Sanofi, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Sanofi, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Sanofi, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Sanofi, Deals By Market, 2011 to YTD 2017 11
Sanofi, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Sanofi Plans to Acquire Medical Device Assets 14
Portal Instruments Raises USD25 Million in Series B Financing 15
Portal Instruments Raises USD11 Million in Series A Venture Financing 16
Abiogen Pharma Enters Into Licensing Agreement With Genzyme 17
Berg Enters into Research Agreement with Sanofi 18
Sanofi and Voluntis Enter into Agreement 19
Sanofi and Verily Life Sciences Form Joint Venture 20
Global Genomics Enters into Research Agreement with Sanofi 21
Google Life Sciences Enters into Agreement with Sanofi 22
Veracyte Enters into Co-Promotion Agreement with Genzyme 23
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 24
Genzyme Extends Co-Promotion Agreement with Veracyte 25
Sanofi Enters into Co-Development Agreement with Medtronic 26
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 27
HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 28
Genzyme Enters Into Co-Marketing Agreement With Veracyte 29
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30
Curetis Enters Into Agreement With Sanofi Pasteur For Unyvero Platform 31
Institut Pasteur Korea Enters Into Co-Development Agreement With Sanofi-Aventis Korea 32
Voluntis and CERITD Enters Into Co-Development Agreement With Sanofi 33
Sanofi Japan and Genzyme Japan Merge 34
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 35
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 36
JHL Biotech Raises USD80 Million in Private Placement of Shares 37
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 38
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 39
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 40
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 41
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 42
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 43
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 44
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 45
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 47
Sanofi Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 48
Lupin May Acquire Pulmojet from Zentiva 50
Nichi-iko Pharma To Acquire Business From Sanofi-Aventis 51
Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 52
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 54
L'Oreal Plans To Sell Its Stake In Sanofi 55
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 56
Sanofi Completes Acquisition Of Pluromed 58
Sanofi-Aventis Completes Acquisition Of Genzyme 59
Sanofi, Key Competitors 61
Sanofi, Key Employees 62
Sanofi, Subsidiaries 64
Sanofi, Joint Venture 77
